Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Strand Therapeutics

start up
United States - Cambridge, Massachusetts
  • 15/12/2022
  • Series A
  • $97,000,000

Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first platform for mRNA smart therapies.

Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.


Related People

Jacob BecraftCo Founder

Jacob Becraft United States - Cambridge, Massachusetts,

Jake Becraft is a synthetic biologist and biotech entrepreneur, as well as the co-founder and CEO of Strand Therapeutics. Strand is situated at the intersection of synthetic biology, immunotherapy, and mRNA therapeutics. Jake started his career developing the SAfER platform at MIT, the world’s first synthetic biology programming language for mRNA. Beyond that work, his broader interests span synthetic biology, the intersection of hard-tech and biologically engineered therapeutics, and biologically engineered organism-machine interfaces. He is an inventor on a multitude of patents in the biotech/gene therapy space and has won numerous awards for his scientific and entrepreneurial achievements, including a Goldwater Scholarship, a Viterbi Fellowship, and an Amgen fellowship. He is an advocate among the life science entrepreneurial ecosystem for supporting founder-driven biotech startups and works to help increase young technical founders in biotech entrepreneurship. Jake has previously served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. He often speaks internationally on the field of synthetic biology, as well as the broader entrepreneurship environment necessary to bring next generation synbio gene therapeutics to market. Jake also serves on the Executive Board of Public Health United, a non-profit focused on educating scientists across disciplines to foster their communication skills in order to become their own scientific ambassadors. He received his PhD in Biological Engineering and Synthetic Biology from MIT and his BS in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. In his free time, he is an avid back-country snowboarder and trains Brazilian Jiu-Jitsu.